Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Tirzepatide in obesitythe surmount clinical study program The GLP-1RA liraglutide has been approved for the pharmacological treatment of obesity and various other GLP-1RA may be approved in the future for this indication as well (81)
Pivotal trials (SURMOUNT series) reported mean weight loss of 15%-22%, peaking at 24% (72-week regimen)
Their targeted action makes them valuable in therapeutics, diagnostics, and personalized medicine applications
The government has warned that regulatory surveillance will continue to be intensified in the coming weeks, with non-compliances dealt with strictly through license cancellations, penalties, and prosecution under applicable laws
US$ 27.01
)
US$ 24.74
US$ 29.12
